2024
|
Invention
|
Systems and methods for event-based tissue activity quantification. Systems and methods for event... |
|
Invention
|
System and method for target or biomarker identification. A method for identifying key targets or... |
|
Invention
|
Systems and methods for automated assessment of artificial tissue. Systems and methods are descri... |
|
Invention
|
Lipotoxic media. The invention provides culture media for cultivating cardiac tissue, methods of ... |
|
Invention
|
Isoindolinone-containing parp inhibitors and methods of use. The present disclosure relates to co... |
|
Invention
|
Spirocyclic parp inhibitors and methods of use. The present disclosure relates to compounds accor... |
|
Invention
|
Homophthalazinone indole parp inhibitors and methods of use. The present disclosure relates to co... |
|
Invention
|
Benzamidazole diazapinone parp inhibitors and methods of use. The present disclosure relates to c... |
|
Invention
|
Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compound.
The invent... |
|
Invention
|
Systems and methods regarding peak exploration and artificial tissue response including for contr... |
|
Invention
|
Systems and methods regarding peak exploration and artificial tissue response including for tissu... |
|
Invention
|
Systems and methods regarding peak exploration and artificial tissue response including for proce... |
|
Invention
|
Systems and methods regarding peak exploration and artificial tissue response including for detec... |
|
Invention
|
Selective fiasma treatment. This disclosure concerns a method of treating or preventing a disease... |
|
Invention
|
Invertible models of cardiac function. Systems and methods are described herein for predicting ch... |
2023
|
Invention
|
Spectral encoding of tissue behavior. Systems, methods, and non-transitory computer readable medi... |
|
Invention
|
System and method for predicting and optimizing clinical trial outcomes. A vector associated with... |
|
Invention
|
Artificial skeletal muscle tissue.
Embodiments described herein relate generally to a three-dime... |
|
Invention
|
Biomarker combinations for prognosis and management of diabetic retinopathy. Methods are describe... |
|
Invention
|
H)-isoquinolinones and intermediate compound. The invention relates to substituted 6-substituted ... |
|
Invention
|
2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors. The present invention is directed to... |
|
Invention
|
Tricyclic phthalazinone parp inhibitors and methods of use. The present disclosure relates to com... |
|
Invention
|
Bicyclic [4,6,0] hydroxamic acids as hdac inhibitors.
The present invention relates to inhibitor... |
|
Invention
|
Artificial skeletal muscle tissue. Embodiments described herein relate generally to a three-dimen... |
|
Invention
|
[6,6] fused bicyclic hdac8 inhibitors.
The present invention is directed to compounds of Formula... |
2022
|
Invention
|
Novel compounds and compositions for the inhibition of nampt.
The present invention relates to c... |
|
Invention
|
Isoindolines as hdac inhibitors.
The present disclosure relates to inhibitors of zinc-dependent ... |
|
Invention
|
Histone deacetylase 6 inhibitor compounds and uses thereof. The present disclosure provides compo... |
|
G/S
|
Pharmaceutical drug development services; pharmaceutical
drug development services via software ... |
|
Invention
|
Monocyclic compounds useful as gpr120 modulators. Provided herein are compounds, compositions inc... |
|
Invention
|
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransfer... |
|
G/S
|
Pharmaceutical drug development services; Pharmaceutical drug development services via software u... |
|
Invention
|
Methods using hdac11 inhibitors.
The present invention provides methods and uses of inhibitors o... |
|
Invention
|
3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors.
The present disclosure rela... |
2021
|
Invention
|
3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors. The present disclosure rela... |
|
Invention
|
Alpha-cinnamide compounds and compositions as hdac8 inhibitors. The present invention relates to ... |
|
Invention
|
Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors. The invent... |
|
Invention
|
Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors. The invention relate... |
|
Invention
|
Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific p... |
|
Invention
|
Integrated system for 3d tissue culture.
Embodiments described herein relate generally to device... |
|
Invention
|
Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors.
The disclosure relates to inhib... |
2020
|
Invention
|
Bicyclic compounds useful as gpr120 modulators. Provided herein are compounds, compositions inclu... |
|
Invention
|
Compounds and compositions for the inhibition of nampt. The present invention relates to compound... |
|
Invention
|
Inhibiting usp19.
The present disclosure is directed to compounds of formulas (I)-(VI), which ar... |
|
Invention
|
Inhibiting trabid.
The present disclosure is directed to compounds of formulas (I)-(VII), which ... |
|
Invention
|
Inhibiting usp36.
The present disclosure is directed to compounds of formulas (I)-(VI), which ar... |
|
Invention
|
A microphysiological platform with embedded electrodes for 3d tissue culture.
Embodiments descri... |
|
Invention
|
Carboxamides as ubiquitin-specific protease inhibitors. The present disclosure relates to modulat... |
2019
|
G/S
|
Cell and tissue culture services, namely, custom design and
development of muscle, vascular, and... |
|
Invention
|
Isoindolines as hdac inhibitors. 3, L, Z, and R are described herein.
|
|
G/S
|
Cell and tissue culture services, namely, custom design and development of muscle, vascular, and ... |
2008
|
G/S
|
Development of pharmaceutical preparations and medicines; Drug discovery services; Pharmaceutical... |